Identifiable Intangible Assets and Goodwill (Tables)

6 Months Ended

Jun. 28, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

The following table provides the components of Identifiable intangible assets:
	June 28, 2020							December 31, 2019
(MILLIONS OF DOLLARS)	Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization
Finite-lived intangible assets
Developed technology rights(a)	$	89,927	$	(64,683	)	$	25,244	$	88,730	$	(63,106	)	$	25,625
Brands	922		(757		)	165		922		(741		)	181
Licensing agreements and other(b)	2,327		(1,226		)	1,101		1,772		(1,191		)	582
	93,176		(66,667		)	26,509		91,425		(65,037		)	26,387
Indefinite-lived intangible assets
Brands	1,991					1,991		1,991					1,991
IPR&D(a)	4,518					4,518		5,919					5,919
Licensing agreements and other(b)	523					523		1,073					1,073
	7,032					7,032		8,983					8,983
Identifiable intangible assets(c)	$	100,208	$	(66,667	)	$	33,541	$	100,408	$	(65,037	)	$	35,370

^(a)  The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect the transfer of $1.4 billion from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux^® (cetuximab), for the treatment of BRAF^V600E-mutant metastatic colorectal cancer after prior therapy.

^(b)  The changes in the gross carrying amount of Licensing agreements and other primarily reflect the transfer of $550 million from Indefinite-lived Licensing agreements and other to finite-lived Licensing agreements and other to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.

^(c) 

The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization.

Schedule of Indefinite Lived Intangible Assets

The following table provides the components of Identifiable intangible assets:
	June 28, 2020							December 31, 2019
(MILLIONS OF DOLLARS)	Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization			Identifiable Intangible Assets, less Accumulated Amortization
Finite-lived intangible assets
Developed technology rights(a)	$	89,927	$	(64,683	)	$	25,244	$	88,730	$	(63,106	)	$	25,625
Brands	922		(757		)	165		922		(741		)	181
Licensing agreements and other(b)	2,327		(1,226		)	1,101		1,772		(1,191		)	582
	93,176		(66,667		)	26,509		91,425		(65,037		)	26,387
Indefinite-lived intangible assets
Brands	1,991					1,991		1,991					1,991
IPR&D(a)	4,518					4,518		5,919					5,919
Licensing agreements and other(b)	523					523		1,073					1,073
	7,032					7,032		8,983					8,983
Identifiable intangible assets(c)	$	100,208	$	(66,667	)	$	33,541	$	100,408	$	(65,037	)	$	35,370

^(a)  The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect the transfer of $1.4 billion from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux^® (cetuximab), for the treatment of BRAF^V600E-mutant metastatic colorectal cancer after prior therapy.

^(b)  The changes in the gross carrying amount of Licensing agreements and other primarily reflect the transfer of $550 million from Indefinite-lived Licensing agreements and other to finite-lived Licensing agreements and other to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array.

^(c) 

The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization.

Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment

Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
	June 28, 2020
	Biopharma		Upjohn		WRDM
Developed technology rights	99	%	1	%	—
Brands, finite-lived	100	%	—		—
Brands, indefinite-lived	42	%	58	%	—
IPR&D	94	%	—		6	%
Licensing agreements and other, finite-lived	99	%	1	%	1	%
Licensing agreements and other, indefinite-lived	100	%	—		—

Schedule of Goodwill

The following table provides the components of and changes in the carrying amount of Goodwill:
(MILLIONS OF DOLLARS)	Biopharma			Upjohn			Total
Balance, December 31, 2019	$	48,202		$	10,451		$	58,653
Other(a)	(155		)	(49		)	(204		)
Balance, June 28, 2020	$	48,047		$	10,401		$	58,449

^(a) 

Primarily represents the impact of foreign exchange.